GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Healios KK (OTCPK:HLOSF) » Definitions » Debt-to-EBITDA

HLOSF (Healios KK) Debt-to-EBITDA : N/A (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Healios KK Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Healios KK's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.76 Mil. Healios KK's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $16.55 Mil. Healios KK's annualized EBITDA for the quarter that ended in Dec. 2024 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Healios KK's Debt-to-EBITDA or its related term are showing as below:

HLOSF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.52   Med: -1.61   Max: -0.58
Current: -1.15

During the past 11 years, the highest Debt-to-EBITDA Ratio of Healios KK was -0.58. The lowest was -3.52. And the median was -1.61.

HLOSF's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.54 vs HLOSF: -1.15

Healios KK Debt-to-EBITDA Historical Data

The historical data trend for Healios KK's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healios KK Debt-to-EBITDA Chart

Healios KK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 -3.52 -1.61 -1.68 -1.22

Healios KK Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.03 -1.13 -1.68 -30.47 N/A

Competitive Comparison of Healios KK's Debt-to-EBITDA

For the Biotechnology subindustry, Healios KK's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healios KK's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Healios KK's Debt-to-EBITDA falls into.


;
;

Healios KK Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Healios KK's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.761 + 16.552) / -14.14
=-1.22

Healios KK's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.761 + 16.552) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Healios KK  (OTCPK:HLOSF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Healios KK Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Healios KK's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Healios KK Business Description

Traded in Other Exchanges
Address
World Trade Center Bldg. 15th Floor, 2-4-1 Hamamatsucho, Minato-ku, Tokyo, JPN, 105-6115
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy.